乳腺体积对早期乳腺癌大分割放疗毒性的影响
该回顾性研究纳入114例接受肿块切除术后全乳放疗的早期乳腺癌患者,其中83例接受大分割放疗(HFRT),31例接受常规分割放疗(CFRT)。中位随访42个月,CFRT组≥2级皮肤毒性发生率显著高于HFRT组(76% vs 28%,P<.0001);在乳腺体积≥1000 cm³亚组中,CFRT组≥2级皮肤毒性有更高趋势(73% vs 38%,P=.057)。
要点
- CFRT组≥2级皮肤毒性发生率显著高于HFRT组(76% vs 28%,P<.0001)。
- 乳腺体积≥1000 cm³亚组中,CFRT组≥2级皮肤毒性有更高趋势(73% vs 38%,P=.057)。
- 后分离>25 cm时,HFRT组2级皮肤毒性43% vs CFRT组57%(P=.67)。
核心结论
- 使用HFRT相比CFRT导致更低的急性皮肤毒性发生率。
- 大乳腺体积(≥1000 cm³)与使用HFRT时更低的急性2级毒性相关,尽管与CFRT相比达到了相似的剂量学。
研究设计与样本
- 回顾性综述,纳入114例诊断为早期乳腺癌并接受肿块切除术和单纯全乳放疗的患者。
- 83例接受HFRT,31例接受CFRT。
- 记录了乳腺癌侧别、分期、分级、雌激素/孕激素受体和人表皮生长因子受体2状态及全身治疗使用情况。
- 随访时间从放疗最后一天计算至最近一次随访日期。
主要发现
- 中位随访42个月。
- CFRT组≥2级皮肤毒性发生率显著高于HFRT组(76% vs 28%;P<.0001)。
- 在乳腺体积≥1000 cm³的患者亚组中,CFRT组≥2级皮肤毒性有更高趋势(73% vs 38%;P=.057)。
- 对于后分离>25 cm,HFRT组2级皮肤毒性患者比例为43%,CFRT组为57%(P=.67)。
- 接受超过总处方剂量105%(包括推量)的乳腺组织体积在HFRT与CFRT之间无显著差异(P=.70)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypofractionated radiation therapy (HFRT) remains underused, despite multiple randomized trials showing the equivalence of HFRT to conventional fractionated radiation therapy (CFRT). We sought to retrospectively review the relationship between breast volume and toxicity for HFRT versus CFRT. METHODS AND MATERIALS: Data from 114 patients who received a diagnosis of early stage breast cancer and were treated with lumpectomy and whole breast radiation alone were reviewed. Breast cancer laterality, stage, grade, estrogen/progesterone receptor and human epidermal growth factor receptor 2 status, and systemic therapy use were recorded. Length of follow-up was calculated using the last day of radiation treatment and the date of the most recent follow-up. RESULTS: The median follow-up was 42 months. A total of 83 patients were treated with HFRT and 31 with CFRT. Rates of grade ≥2 skin toxicity were significantly higher in patients undergoing CFRT compared with HFRT (76% vs 28%; P < .0001). In a subset of patients with breast volume ≥1000 cm3, grade ≥2 skin toxicity trended higher for CFRT patients (73% vs 38%; P = .057). For posterior separation >25 cm, the percentage of patients with grade 2 skin toxicity was 43% for HFRT versus 57% for CFRT (P = .67). The volume of breast tissue receiving >105% of the total prescription dose, including boost, was not significantly different for HFRT versus CFRT (P = .70). CONCLUSIONS: Use of HFRT resulted in lower acute skin toxicity rates compared with CFRT. Large breast size (volume ≥1000 cm3) was associated with lower acute grade 2 toxicity with the use of HFRT despite achieving similar dosimetry compared with CFRT.
引用
- Butler-Xu YS, Marietta M, Zahra A, et al. The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients. Adv Radiat Oncol. 2018. PMID: 31011671. doi:10.1016/j.adro.2018.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。